

FOI 1905

20/09/23

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Response 1:

| | |
|----------------------------|-----|
| • Abatacept [Orencia] | 91 |
| • Adalimumab [Humira] | 37 |
| • Adalimumab Biosimilars | 494 |
| • Apremilast [Otezla] | 1 |
| • Baricitinib [Olumiant] | 56 |
| • Bimekizumab [Bimzelx] | 0 |
| • Certolizumab [Cimzia] | 71 |
| • Etanercept [Enbrel] | 15 |
| • Etanercept Biosimilars | 187 |
| • Filgotinib [Jyseleca] | 0 |
| • Golimumab [Simponi] | 78 |
| • Guselkumab [Tremfya] | 4 |
| • Infliximab [Remicade] | 1 |
| • Infliximab Biosimilars | 27 |
| • Ixekizumab [Taltz] | 41 |
| • Risankizumab [Skyrizi] | 0 |
| • Rituximab [MabThera] | 0 |
| • Rituximab Biosimilars | 92 |
| • Sarilumab [Kevzara] | 12 |
| • Secukinumab [Cosentyx] | 129 |
| • Tocilizumab [Ro Actemra] | 43 |
| • Tofacitinib [Xeljanz] | 12 |
| • Upadacitinib [Rinvoq] | 16 |
| • Ustekinumab [Stelara] | 0 |

Question 2:

Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

| | |
|--------------------------|-----|
| • Abatacept [Orencia] | 0 |
| • Adalimumab [Humira] | 15 |
| • Adalimumab Biosimilars | 173 |
| • Apremilast [Otezla] | 0 |
| • Bimekizumab [Bimzelx] | 0 |
| • Certolizumab [Cimzia] | 26 |
| • Etanercept [Enbrel] | 4 |
| • Etanercept Biosimilars | 77 |
| • Golimumab [Simponi] | 24 |
| • Guselkumab [Tremfya] | 4 |
| • Infliximab [Remicade] | 0 |
| • Infliximab Biosimilars | 7 |
| • Ixekizumab [Taltz] | 30 |
| • Risankizumab [Skyrizi] | 0 |
| • Secukinumab [Cosentyx] | 77 |
| • Tofacitinib [Xeljanz] | 5 |
| • Upadacitinib [Rinvoq] | 1 |
| • Ustekinumab [Stelara] | 0 |

Email: Foi.Team@Southerntrust.hscni.net